Drug discovery based on ferroptosis control for cancers and neurodegenerative diseases (lead FC-004), a Keio spin-off.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Series A FerroptoCure raised 960 million yen in a Series A (460 equity from ANRI, TUS Innovation Capital and others, plus 500 in AMED grants). | $6.2M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.